Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death

Heart

Volumn 98, Issue 1, 2012, Pages 48-53

  Hunter, Ross J ^a   McCready, James ^b   Diab, Ihab ^a   Page, Stephen P ^a   Finlay, Malcolm ^b   Richmond, Laura ^a   French, Antony ^c   Earley, Mark J ^a,d   Sporton, Simon ^a,d   Jones, Michael ^e   Joseph, Jubin P ^e   Bashir, Yaver ^e   Betts, Tim R ^e   Thomas, Glyn ^c   Staniforth, Andrew ^f   Lee, Geoffrey ^g   Kistler, Peter ^g   Rajappan, Kim ^e   Chow, Anthony ^b   Schilling, Richard J ^a,d  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d LONDON BRIDGE HOSPITAL   (United Kingdom)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^f NUH Hospitals Trust   (United Kingdom)

^g BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; WARFARIN;

ADULT; ARTERIOVENOUS FISTULA; ARTICLE; AUSTRALIA; BRAIN HEMORRHAGE; BURN; CATHETER ABLATION; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DISEASE REGISTRY; FEMALE; HEART ATRIUM FIBRILLATION; HEART TAMPONADE; HEMATOMA; HUMAN; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; KIDNEY ARTERY EMBOLISM; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PULMONARY ARTERY PERFORATION; PULMONARY VASCULAR DISEASE; PULMONARY VEIN OBSTRUCTION; RISK REDUCTION; SINUS RHYTHM; STOMACH DISEASE; STOMACH RETENTION; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNITED KINGDOM;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CASE-CONTROL STUDIES; CATHETER ABLATION; FEMALE; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84155163258     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-300720     Document Type: Article

References (29)

1. Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982;306:1018-22. (Pubitemid 12155370)
2. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33. (Pubitemid 35417773)
3. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004;109:1509-13. (Pubitemid 38420179)
4. Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001;104:292-6. (Pubitemid 32666950)
5. Friberg L, Hammar N, Edvardsson N, et al. The prognosis of patients with atrial fibrillation is improved when sinus rhythm is restored: report from the Stockholm Cohort of Atrial Fibrillation (SCAF). Heart 2009;95:1000-5.
6. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-77. (Pubitemid 351860859)
7. Oral H, Chugh A, Ozaydin M, et al. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation 2006;114:759-65. (Pubitemid 44268226)
8. Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 2003;42:185-97. (Pubitemid 36851403)
9. Nademanee K, Schwab MC, Kosar EM, et al. Clinical outcomes of catheter substrate ablation for high-risk patients with atrial fibrillation. J Am Coll Cardiol 2008;51:843-9. (Pubitemid 351253744)
10. Bunch TJ, Crandall BG, Weiss JP, et al. Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. J Cardiovasc Electrophysiol 2011;22:839-45.
11. Sonne K, Patel D, Mohanty P, et al. Pulmonary vein antrum isolation, atrioventricular junction ablation, and antiarrhythmic drugs combined with direct current cardioversion: survival rates at 7 years follow-up. J Interv Card Electrophysiol 2009;26:121-6.
12. Hunter RJ, Berriman T, Diab I, et al. Long term efficacy of catheter ablation for AF: impact of additional targeting of fractionated electrograms. Heart 2010;96:1372-8.
13. Bunch TJ, Asirvatham SJ, Friedman PA, et al. Mortality benefit and quality of life outcomes in patients undergoing curative ablation for atrial fibrillation: comparison with a disease-matched community population. Circulation 2006;114:602.
14. Themistoclakis S, Corrado A, Marchlinski FE, et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol 2010;55:735-43.
15. Calkins H, Brugada J, Packer DL, et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society. Europace 2007;9:335-79.
16. Calkins H, Brugada J, Packer DL, et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2007;4:816-61. (Pubitemid 46850611)
17. Lee SH, Tai CT, Hsieh MH, et al. Predictors of early and late recurrence of atrial fibrillation after catheter ablation of paroxysmal atrial fibrillation. J Interv Card Electrophysiol 2004;10:221-6.
18. Oral H, Knight BP, Ozaydin M, et al. Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. J Am Coll Cardiol 2002; 40:100-4. (Pubitemid 34701383)
19. Nieuwlaat R, Prins MH, Le Heuzey JY, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J 2008;29:1181-9. (Pubitemid 351844895)
20. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005;26:2422-34. (Pubitemid 41552972)
21. http://www.statistics.gov.uk/statbase/Product.asp?vlnk=14409.
22. http://www.isdscotland.org/isd/6537.html
23. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70. (Pubitemid 32537350)
24. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-72.
25. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8.
26. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996;348:7-12. (Pubitemid 26237238)
27. Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992;20:527-32.
28. Hohnloser SH, Crijns HJ, van EM, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78.
29. Nieuwlaat R, Olsson SB, Lip GY, et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J 2007;153:1006-12. (Pubitemid 46823965)